BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

  • STATUS
    Recruiting
  • End date
    Feb 14, 2023
  • participants needed
    62
  • sponsor
    Don Dizon
Updated on 14 April 2021
Investigator
Roxanne Wood, BA
Primary Contact
The Miriam Hospital (2.3 mi away) Contact
+2 other location
ct scan
cancer
measurable disease
carcinoma
metastasis
neutrophil count
tumor cells
cancer chemotherapy
spiral computed tomography
solid tumour
ovarian cancer
fallopian tube
taxane
ovarian epithelial cancer
clear cell adenocarcinoma

Summary

Preclinical and early-phase clinical data suggest that immune modulation represents a treatment strategy that is worthy of further investigation in relapsed epithelial ovarian cancer. One method by which tumor cells may evade immune surveillance is by activation of the programmed cell death (PD-1) pathway, mediated by expression of PD-1 on the surface of T lymphocytes, which conveys an inhibitory signal after binding to its ligand PD-L1 on the surface of tumor cells. Nivolumab and Ipilimumab have shown activity as monotherapies in solid tumors and very early data suggest that nivolumab may be particularly active for ovarian clear cell carcinoma.(Hamanishi et al., 2015). Given the uniformly poor prognosis for patients with clear cell carcinoma in general, we are interested in formally evaluating this agent in all extra-renal clear cell carcinomas.

Details
Condition Adenocarcinoma, Ovarian disorder, Fallopian Tube Cancer, Ovarian Cancer, Clear cell adenocarcinoma, Ovarian Function, Primary Peritoneal Cancer, Primary Peritoneal Carcinoma, Recurrent Ovarian Cancer, Extra Renal Origin, Malignant Adenoma, ovarian carcinomas, cancer, ovarian, cancer ovarian, cancer of the ovary, clear cell carcinoma, fallopian tube cancers, ovarian tumors
Treatment Ipilimumab, Nivolumab
Clinical Study IdentifierNCT03355976
SponsorDon Dizon
Last Modified on14 April 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients must have a recurrent, advanced, or metastatic pure clear cell carcinoma of ovarian, fallopian tube, primary peritoneal, or extra-renal origin
All patients must submit representative tissue from their malignancy
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as 20 mm with conventional techniques or as 10 mm with spiral CT scan, MRI, or calipers by clinical exam
Patients with a clear cell carcinoma of ovarian, fallopian or primary peritoneal origin must have progressed after at least one prior platinum and taxane based chemotherapy regimen. Patients with extra-renal clear cell cancer (including other GYN) cancers must have progressed after at least one prior regimen for advanced/metastatic disease. Radiation therapy (including the use of chemotherapy as a radiosensitizer) will not count as a prior systemic regimen
No prior anti-PD-1, PD-L1 or CTLA-4 antibody
Age 18
ECOG performance status 0 to 1
Participants must have normal organ and marrow function as defined below
leukocytes 3,000/mcL absolute neutrophil count 1,500/mcL platelets 100,000/mcL
total bilirubin within normal institutional limits EXCEPTIONS: conjugated
hyperbilirubinemia; Gilbert's syndrome, both of which will allow a total
bilirubin <3.0mg/dL <5xULN is liver metastases are present A value below the
LLN is acceptable if confirmed appropriate by the treating MD
AST(SGOT)/ALT(SGPT) 2.5 institutional upper limit of normal creatinine 1.5 X
ULN (upper limit of normal) OR creatinine clearance 50 mL/min
Adequate thyroid function within 28 days prior to registration defined as serum TSH in normal range. Patients on thyroid hormone supplementation are allowed provided the serum TSH is within normal limits
Subjects must have a resting baseline O2 saturation by pulse oximetry of 92% at rest. This should be documented within two weeks of registration
Reproductive status
Women of childbearing potential (WOCBP) must use method(s) of contraception. Given there is insufficient information to assess teratogenicity (preclinical studies have not been done), a highly effective method(s) of contraception (failure rate of less than 1% per year) is required as determined by the treating investigator. WOCBP must follow instructions for birth control. For all women who discontinue protocol treatment, contraception should be continued for five months following the last dose of therapy
WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to the start of registration
Women who are not of childbearing potential (ie, who are postmenopausal (lack of menses > 24 months) or surgically sterile) and azospermic men do not require contraception
Women must not be breastfeeding (document for all)
Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1 % per year. The investigator shall review contraception methods and the time period that contraception must be followed
Men that are sexually active with WOCBP must follow instructions for birth control when the half life of the investigational drug is greater than 24 hours, contraception should be continued for a period of 7 months after discontinuation of treatment
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

Participants who have had prior therapy with nivolumab or with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune check point pathways
Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. Patients using endocrine therapy as treatment for their index cancer must be off of treatment for one week (7 days) prior to entering the study
Participants who have not recovered from clinically significant adverse events to <grade 2 and which are related to prior treatment agents administered
Participants who are receiving any other investigational agents
Participants with known brain metastases are excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
History of severe hypersensitivity reaction to any monoclonal antibody
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring antibiotics, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant women are excluded from this study
Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer are excluded if there is any evidence of other malignancy being present within the last three years. However, patients with a malignancy that is not-likely to require treatment in the next 2 years, such as a completely resected, early stage breast cancer, are eligible
Patients who have received prior chemotherapy within the last three years for any other cancer other than for clear cell cancer
In order for patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) to be eligible, they must be on a stable highly active antiretroviral therapy (HAART) regimen, have CD4 counts > 350, with no detectable viral load on quantitative PCR within 4 weeks of registration
Patients with treated hepatitis virus infections (Hepatitis B or Hepatitis C) are eligible if they have been definitively treated for 6 months, have no detectable viral load on quantitative PCR, and LFTs meet eligibility requirements within 4 weeks of screening
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of day 1 study drug administration
Any other medical condition that will prevent the safe administration of study drugs in the opinion of the treating physician
Planned concomitant, non-protocol directed anti-cancer therapy during the trial
Grade 2 peripheral neuropathy
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note